McKenzie training in patients with early stages of ankylosing spondylitis: results of a 24-week controlled study

被引:2
|
作者
Rosu, O. M. [1 ]
Ancuta, C. [1 ,2 ]
机构
[1] Univ Med & Pharm Gr T Popa, Rheumatol Rehabil Dept, Iasi, Romania
[2] Clin Rheumatol Dept, Rheumatol Dept 2, Iasi, Romania
关键词
Spondylitis; ankylosing; Exercise therapy; Spine; LOW-BACK-PAIN; 2 EXERCISE INTERVENTIONS; MANAGEMENT; THERAPY; RECOMMENDATIONS; DISEASE; UPDATE;
D O I
暂无
中图分类号
R49 [康复医学];
学科分类号
100215 ;
摘要
Background. It is widely accepted that patient education and regular exercises could improve pain, function and maintain posture in ankylosing spondylitis (AS). Aim. The main aim of our study was to demonstrate the benefits of a specific, McKenzie training focusing on pain, spine flexibility, disease activity and function, as well as chest expansion in AS. Design. Controlled study. Setting. Rheumatology and Rehabilitation Department. Population. Patients with early AS. Methods. Prospective 24-week controlled study in 52 patients with early AS (modified 1984 New York criteria) randomly assigned to perform either McKenzie training (28 AS) or classic kinetic exercises (24 AS). Efficacy parameters comprising pain, lumbar spine mobility (modified Schober test, mST; finger-to-floor distance, FFD; BASMI), chest expansion (CE), disease activity (BASDAI) and function (BASFI) were evaluated during three visits (week 0, 12 and 24 after the initiation of the kinetic program). The exercise protocol consisted of 50-minute sessions performed 3 times weekly for 24 weeks, with a 12-week learning module assisted by a trained physical therapist in the outpatient rheumatology and rehabilitation department, and a 12-week module performed individually at home. Only subjects attending the kinetic program on a regular basis (at least 2 times weekly, at least 60 attended sessions during the study) were and accepted for the final evaluation. Results. After 12 and 24 weeks of exercises we reported significant improvement in pain (P=0.015 and P=0.003), metrology (mST: P=0.001 and P=0.001; FFD: P=0.002 and P=0.001; BASMI: P=0.001 and P=0.001), disease activity (BASDAI: P=0.004 and P=0.001) and function (BASFI: P=0.001 at both visits) in the McKenzie group. mST, BASDAI, BASFI and BASMI also improved at both visits in controls (P<0.05), while CE and FFD significantly changed only in long-term assessment (P<0.05). Intergroup analysis demonstrated significant differences in all measurements including favoring AS in the McKenzie exercises (P=0.001). Conclusion. A specific McKenzie training should be included in the standard-care of AS aiming to improve pain, posture and function, especially in early axial disease. Clinical Rehabilitation Impact. A specific McKenzie training should be included in the standard-care of AS
引用
收藏
页码:261 / 268
页数:8
相关论文
共 50 条
  • [1] Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a 24-week randomized, placebo-controlled trial (ASSERT)
    van der Heijde, D
    Dijkmans, B
    Geusens, P
    Sieper, J
    DeWoody, K
    Williamson, R
    Braun, J
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 403 - 403
  • [2] Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study
    Song, I-H
    Heldmann, F.
    Rudwaleit, M.
    Haibel, H.
    Weiss, A.
    Braun, J.
    Sieper, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) : 1108 - 1110
  • [3] GOLIMUMAB, A NEW, HUMAN, TNFα ANTIBODY, IN ANKYLOSING SPONDYLITIS (AS): 24-WEEK EFFICACY AND SAFETY RESULTS OF THE GO-RAISE STUDY
    Braun, Jurgen
    Davis, John
    van der Heijde, Desiree
    Deodhar, Atul
    Diekman, Laura
    Sieper, Joachim
    Kim, Sung Il
    Han, John
    Hsu, B.
    Inman, Robert
    [J]. RHEUMATOLOGY, 2009, 48 : I57 - I57
  • [4] Switching from infliximab to etanercept 50 mg/once weekly in resistant or intolerant patients with ankylosing spondylitis: 24-week results.
    Laura, N
    Maurizio, B
    Fabrizio, C
    Giovanni, P
    Lara, S
    Daniela, C
    Carlotta, N
    Ignazio, O
    Carlo, S
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S638 - S638
  • [5] BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY
    Van der Heijde, D.
    Baraliakos, X.
    Dougados, M.
    Brown, M.
    Poddubnyy, D.
    Van den Bosch, F.
    Haroon, N.
    Xu, H.
    Tomita, T.
    Gensler, L. S.
    Oortgiesen, M.
    Fleurinck, C.
    Vaux, T.
    Marten, A.
    Deodhar, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 12 - 13
  • [6] Effects of etanercept (ENBREL®) on spinal and hip bone mineral density in patients with ankylosing spondylitis:: 24-week data.
    Davis, JC
    Fleischmann, RM
    Molitor, J
    Jimenez, RAH
    Mease, PJ
    Inman, RD
    Tsuji, WH
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S177 - S177
  • [7] RAPID IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES WITH CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS: 24-WEEK RESULTS OF RAPID-AXSPA STUDY
    Sieper, J.
    Kivitz, A.
    van Tubergen, A.
    Deodhar, A.
    Coteur, G.
    Woltering, F.
    Landewe, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 287 - 287
  • [8] Efficacy of Certolizumab Pegol on Signs and Symptoms of Axial Spondyloarthritis Including Ankylosing Spondylitis: 24-Week Results of a Double-Blind Randomised Placebo-Controlled Phase 3 Study
    Lunzer, R.
    [J]. JOURNAL FUR MINERALSTOFFWECHSEL, 2014, 21 (01): : 36 - +
  • [9] Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
    Landewe, R.
    Braun, J.
    Deodhar, A.
    Dougados, M.
    Maksymowych, W. P.
    Mease, P. J.
    Reveille, J. D.
    Rudwaleit, M.
    van der Heijde, D.
    Stach, C.
    Hoepken, B.
    Fichtner, A.
    Coteur, G.
    de Longueville, M.
    Sieper, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 39 - 47
  • [10] Bimekizumab Improves Signs and Symptoms Including Inflammation in Patients with Active Ankylosing Spondylitis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study
    van der Heijde, Desiree
    Baraliakos, Xenofon
    Dougados, Maxime
    Brown, Matthew
    Poddubnyy, Denis
    Van den Bosch, Filip
    Haroon, Nigil
    Xu, Huji
    Tomita, Tetsuya
    Gensler, Lianne
    Oortgiesen, Marga
    Fleurinck, Carmen
    de Peyrecave, Natasha
    Vaux, Thomas
    Marten, Alexander
    Deodhar, Atul
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 816 - 819